S Biomedics Co Ltd

S Biomedics Co Ltd has a liquidity position that is currently medium, with a debt-to-equity ratio of 1.68 and a current ratio of 1.61. The company's cash and equivalents amount to 6,085,001,730 KRW, but this is insufficient to cover its long-term debt of 14,609,269,060 KRW, resulting in a negative net cash position. The company's free cash flow is negative at -9,357,162,850 KRW, indicating a significant cash outflow from operations after capital expenditures. Profitability metrics show a challenging financial position for S Biomedics Co Ltd. The company reported a net loss of -8,122,245,550 KRW and an operating loss of -8,276,383,440 KRW. Return on equity is -0.9361, and return on assets is -0.1971, both significantly below the industry median for pharmaceutical companies. These metrics suggest the company is not generating returns that meet the cost of capital or industry benchmarks. The company operates through two segments: Medical Devices and Stem Cell Therapeutics. The Medical Devices segment is engaged in the manufacture and sale of medical devices and cosmetics, while the Stem Cell Therapeutics segment focuses on stem cell therapies and R&D. However, the financial data does not provide a breakdown of revenue by segment, making it difficult to assess the contribution of each segment to the company's overall performance. Looking at the company's growth trajectory, the financial data does not provide forward-looking revenue projections or historical growth rates. The company's operating cash flow is negative at -3,980,548,650 KRW, and capital expenditures are -4,383,836,560 KRW, indicating a significant investment in the business. However, the negative net income and operating income suggest that the company is not currently generating sufficient revenue to cover its costs and investments. The risk assessment for S Biomedics Co Ltd indicates a medium liquidity risk and a low dilution risk. The company's key financial flag is a negative net cash position after subtracting total debt, which could impact its ability to meet short-term obligations. The company's dilution risk is low, with no near-term pressure for additional share issuance. However, the company's negative net income and operating income could affect its ability to maintain or grow its equity base without external financing. Recent events and disclosures for S Biomedics Co Ltd include analyst estimates that suggest a mean price target of 65,000 KRW, with a mean recommendation of 2.00 (1=strong buy, 5=strong sell). The company has one buy recommendation and no strong buy or hold recommendations, indicating a cautious outlook from analysts. The company's financial performance and liquidity position are key factors influencing these recommendations.